Skip to content

HIVE

NASDAQ

HIVE Digital Technologies Ltd

Information Technology
Technology

$2.79

0.4%

Updated Today 11:10 AM ET

Report Card

HIVE at a glance — five pillars scored 0–100 from real filed financials.

Value
Growth
Profitability
Health
0
Dividends
0

Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.

Key Metrics

Market Cap

$0.00

P/E

Forward P/E (est.)

ROE

Revenue Growth

EPS Growth

Profit Margin

FCF Yield

Debt / Equity

ROIC

Interest Coverage

Current Ratio

1.1x

Dividend Yield

Implied Growth (rev. DCF)

Rating Score

0/100

Business Overview
Research

HIVE Digital Technologies Ltd (HIVE) is a small-cap company in the Technology industry, part of the Information Technology sector of the S&P 500.

In its latest reported year it generated about $297.79M in revenue and posted a net loss of $148.45M.

Our model rates HIVE Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.

Revenue Growth
Research

2Y CAGR

61.3%

Revenue moved from $114.47M in 2024 to $297.79M in 2026, a 61.3% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.

Profitability

Gross Margin

-21.0%

Operating Margin

Net Margin

-49.8%

ROE

Debt Analysis
Research
1/1 checks passedShort-term bills covered

Total Debt

Net Debt

Net Debt / EBITDA

Debt / Equity

Leverage: debt-to-equity is n/a, with a current ratio of 1.1x. Detailed balance-sheet leverage is limited for this name.

Cash Flow Analysis
Research

Operating CF

$62.34M

Free Cash Flow

$62.34M

FCF Margin

20.9%

In the latest year HIVE Digital Technologies Ltd produced about $62.34M of operating cash flow and $62.34M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.

Valuation Analysis
Research

P/E

P/S

P/B

EV / EBITDA

HIVE trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.

Metrics vs. Sector Range

Where HIVE sits versus its Information Technology sector peers in the S&P 500.

TTM P/E
Forward P/E
P/S ratio
Revenue growth
EPS growth
Gross margin
-21.0%Weak
Net margin
ROE

Bands show the middle half (25th–75th percentile) of the 98 Information Technology companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.

Sector Peer Comparison

How HIVE stacks up against its Information Technology peers — valuation, profitability, and growth versus the sector median.

In the Information Technology sector (230 S&P 500 companies), HIVE ranks #156 of 230 by our overall rating.

P/E vs sector

median 38x

ROE vs sector

median 17.5%

Growth vs sector

median 17.7%

Sector rank

#156

of 230 by rating

CompanyP/ERev Gr.Rating
HIVEThis stockNot rated
ACIWNot rated
ADEANot rated
AGYSNot rated
AIPNot rated
ALKTNot rated
ALRMNot rated
AMPLNot rated
Information Technology median38x17.7%0/100
Compare side by side

Peers are the closest Information Technology companies by sub-industry and size. Sector median is across all 230 S&P 500 names in the sector. Educational, not a recommendation.

5-Year Projection Model

Project revenue → earnings → price. Edit the assumptions to build your own case.

2030 price target (Base Case)

$0.00 $0.00

vs. $2.79 today · expected CAGR -27%-19%

Metric20262027202820292030
Revenue$321.61M$347.34M$375.13M$405.14M$437.55M
Net income$9.65M$10.42M$11.25M$12.15M$13.13M
EPS$0.04$0.04$0.04$0.05$0.05
Share price (low)$0.43$0.47$0.50$0.55$0.59
Share price (high)$0.72$0.78$0.84$0.91$0.98
CAGR (low–high)-84% / -74%-59% / -47%-43% / -33%-34% / -24%-27% / -19%

Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.

Bull Case

The case for HIVE:

  • As an established S&P 500 member in Information Technology, it brings scale and a long operating history.
Bear Case

The case against HIVE:

  • Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Key Risks
Research

Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.

Investment Thesis
Research

On balance, the picture is mixed: HIVE Digital Technologies Ltd is a small-cap information technology business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.

Analyst Ratings

What 10 Wall Street analysts covering HIVE recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.

Buy
consensus · score 4.1 / 5 across 10 analysts
Strong Buy 2Buy 7Hold 1Sell 0Strong Sell 0

Latest SEC Filings

HIVE's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.

HIVE — frequently asked questions

Is HIVE a good stock to buy?

We don't give buy or sell advice. Review HIVE Digital Technologies Ltd's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.

Where does HIVE's data come from?

Live price data plus real fundamentals and 5-year financials pulled directly from HIVE Digital Technologies Ltd's SEC filings — refreshed automatically, not hand-entered.

How is the 5-year projection for HIVE calculated?

It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.

Is this HIVE analysis financial advice?

No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell HIVE. Always do your own research and consider a licensed professional.

Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.

Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.